Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/358283
Cost Benefit Analysis of Research and Development of Top 10 Biotechnology Companies
Description:
Biotechnology Products in Late Stages of Development Promise Market Growth
The top ten biotechnology companies in the United States have 186 products in research and development (R&D) and of these, nearly 20 percent are in phase III of development. These products are likely to have substantial impact on market growth in the next two to three years. The biotechnology industry is optimistic about market growth despite the recent spate of drug recalls in the pharmaceutical and biotechnology industries, which wiped out billion’s of dollars of market capital. Since the fundamentals of product development are sound, the companies are confident of overcoming these setbacks and accelerating growth.
This Frost & Sullivan research service examines the risk-return and cost-benefit profiles of research and development of the top ten biotechnology companies in the United States. The study incorporates a model to evaluate and provide an outlook for each of these companies. It also analyzes the possible blockbuster products in the product pipelines.
High Returns from Biotechnology Stocks Continue to Drive Investor Interest
The biotechnology market thrives on risk taking. From 1994 to 2005, the top ten companies have returned an exceptional figure of close to 27 percent on stock price appreciation. In the next year, this number is expected to reach 24-25 percent, despite a few setbacks in the industry. Established companies such as Amgen, Chiron, Genentech, and Genzyme are forecast to continue leading the market. Such high levels of returns from biotechnology stocks are likely to sustain investor interest in the industry and maintain focus on new R&D projects. Biogen IDEC, which has delivered the highest returns of 43.5 percent from 1994 to 2005, has a risk rating of ‘moderate/high’, says the analyst of this research. Similarly, Gilead which has returned 29.5 percent, much above the industry average, has the highest risk rating of “very risky”.
Licensing Deals and Risk Management Reduces the Perils Associated with Failure
As a drug moves through more advanced stages of R&D, the losses associated with failure are naturally expected to increase. To counter this situation, biotech companies could enter into licensing deals and implement risk management solutions. Industry trends point toward an increase in licensing and partnerships between companies. By sharing the risks and profits, companies can eliminate or decrease the jeopardy associated with failures. The partnerships between big pharma and biotech are likely to be the trendsetters in the biotech industry, notes the analyst. With the technical expertise of biotechnology and the marketing skill of big pharmas, the collaborations are expected to be very successful.
The top ten biotechnology companies in the United States have 186 products in research and development (R&D) and of these, nearly 20 percent are in phase III of development. These products are likely to have substantial impact on market growth in the next two to three years. The biotechnology industry is optimistic about market growth despite the recent spate of drug recalls in the pharmaceutical and biotechnology industries, which wiped out billion’s of dollars of market capital. Since the fundamentals of product development are sound, the companies are confident of overcoming these setbacks and accelerating growth.
This Frost & Sullivan research service examines the risk-return and cost-benefit profiles of research and development of the top ten biotechnology companies in the United States. The study incorporates a model to evaluate and provide an outlook for each of these companies. It also analyzes the possible blockbuster products in the product pipelines.
High Returns from Biotechnology Stocks Continue to Drive Investor Interest
The biotechnology market thrives on risk taking. From 1994 to 2005, the top ten companies have returned an exceptional figure of close to 27 percent on stock price appreciation. In the next year, this number is expected to reach 24-25 percent, despite a few setbacks in the industry. Established companies such as Amgen, Chiron, Genentech, and Genzyme are forecast to continue leading the market. Such high levels of returns from biotechnology stocks are likely to sustain investor interest in the industry and maintain focus on new R&D projects. Biogen IDEC, which has delivered the highest returns of 43.5 percent from 1994 to 2005, has a risk rating of ‘moderate/high’, says the analyst of this research. Similarly, Gilead which has returned 29.5 percent, much above the industry average, has the highest risk rating of “very risky”.
Licensing Deals and Risk Management Reduces the Perils Associated with Failure
As a drug moves through more advanced stages of R&D, the losses associated with failure are naturally expected to increase. To counter this situation, biotech companies could enter into licensing deals and implement risk management solutions. Industry trends point toward an increase in licensing and partnerships between companies. By sharing the risks and profits, companies can eliminate or decrease the jeopardy associated with failures. The partnerships between big pharma and biotech are likely to be the trendsetters in the biotech industry, notes the analyst. With the technical expertise of biotechnology and the marketing skill of big pharmas, the collaborations are expected to be very successful.
Contents:
1. Overview of the Biotechnology Industry
1. Overview of the Biotechnology Industry
1. Industry Structure
2. Technology and Processes
3. Research and Development Process
4. Top 10 Companies
5. Disclaimer
2. Frost & Sullivan Awards
1. Best Cost-Benefit Value Award
2. Best Risk-Return Value Award
2. Company Analysis
1. Methodology
1. Risk Return Analysis
2. Cost Benefit Analysis
2. Amgen Inc.
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
3. Biogen Idec Inc.
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
4. Chiron Corporation
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
5. Genentech, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
6. Genzyme Corporation
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
7. Gilead Sciences, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
8. InterMune, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
9. MedImmune, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
10. Millennium Pharmaceuticals, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
11. Serono Inc.
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
3. Industry Analysis
1. Industry Analysis
1. Risk Return Analysis
2. Cost Benefit Analysis
4. Decision Support Databases
1. Biotechnology & Healthcare
1. Biotechnology Companies
2. Biotechnology Employees
3. Percentage Government Biotechnology Investment
4. Biotechnology Patents Granted by USPTO
5. Healthcare Expenditure
1. Overview of the Biotechnology Industry
1. Industry Structure
2. Technology and Processes
3. Research and Development Process
4. Top 10 Companies
5. Disclaimer
2. Frost & Sullivan Awards
1. Best Cost-Benefit Value Award
2. Best Risk-Return Value Award
2. Company Analysis
1. Methodology
1. Risk Return Analysis
2. Cost Benefit Analysis
2. Amgen Inc.
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
3. Biogen Idec Inc.
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
4. Chiron Corporation
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
5. Genentech, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
6. Genzyme Corporation
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
7. Gilead Sciences, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
8. InterMune, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
9. MedImmune, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
10. Millennium Pharmaceuticals, Inc
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
11. Serono Inc.
1. Company Profile
2. Research and Development
3. Risk Return Analysis
4. Cost Benefit Analysis
3. Industry Analysis
1. Industry Analysis
1. Risk Return Analysis
2. Cost Benefit Analysis
4. Decision Support Databases
1. Biotechnology & Healthcare
1. Biotechnology Companies
2. Biotechnology Employees
3. Percentage Government Biotechnology Investment
4. Biotechnology Patents Granted by USPTO
5. Healthcare Expenditure
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Wednesday, May 22, 2013
3:02:06 AM
3:02:06 AM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Cost Benefit Analysis of Research and Development of Top 10 Biotechnology Companies
Web Address
http://www.researchandmarkets.com/reports/358283
Office Code
OC8DIQSPQPPXUR
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic - Site License |
|
EURO€ 3,036.00 |
|---|---|---|
| Electronic - Enterprisewide |
|
EURO€ 4,189.00 |
| Electronic and Hard Copy (PDF) - Enterprisewide |
|
EURO€ 4,574.00 + EUR€ 50.00 Shipping/Handling * |
| Electronic and Hard Copy (PDF) - Site License |
|
EURO€ 3,421.00 + EUR€ 50.00 Shipping/Handling * |
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Wednesday, May 22, 2013
3:02:06 AM
3:02:06 AM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp